Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage
ayahuasca, show some potential to treat depression, anxiety, and addiction. Importantly …

This paper provides a critical review of several possible mechanisms at different levels of
analysis underlying the effects and therapeutic potential of psychedelics. At the (1) …

Psychedelics make up a group of psychoactive compounds that induce hallucinogenic
effects by activating the serotonin 2A receptor (5-HT2AR). Clinical trials have demonstrated …

Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca,
DMT, psilocybin, and LSD, in stress-related disorders. These substances induce cognitive …

Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in
psychiatric research and therapy. However, no modern studies have evaluated differences …

The psychedelic psilocybin is being investigated for the treatment of depression and anxiety.
Unclear is whether antidepressant treatments interact with psilocybin. The present study …

Abstract N, N-dimethyltryptamine (DMT) is distinct among classic serotonergic psychedelics
because of its short-lasting effects when administered intravenously. Despite growing …

Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric
research and therapy. However, no modern studies have evaluated subjective and …

Psychedelic drugs have reemerged as tools to treat several brain disorders. Cultural
attitudes toward them are changing, and scientists are once again investigating the neural …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …